Skip to content
Medical Health Aged Care

World Hepatitis Summit 2024 Convenes in Lisbon

World Hepatitis Alliance 3 mins read

The World Hepatitis Summit (WHS) 2024 Will Bring Together Global Experts to Discuss the Latest Advances in Hepatitis Prevention, Diagnosis and Treatment

LONDON, ENGLAND / ACCESSWIRE / April 4, 2024 / The World Hepatitis Summit (WHS) 2024 convenes in Lisbon from 9 - 11 April and will bring together global experts to discuss the latest advances in hepatitis prevention, diagnosis and treatment.

World Hepatitis Summit 2024
World Hepatitis Summit 2024
WHS logo

Policy makers, civil society members, representatives from the private sector, academics and other stakeholders will convene to deliberate and share updates on innovative approaches to increase access to testing, vaccination and treatment services for viral hepatitis. Deliberations will also focus on addressing stigma and discrimination and advocating for funding, with an aim for viral hepatitis elimination by 2030.

At the Summit, the World Hepatitis Alliance (WHA) and The European Centre for Disease Prevention and Control (ECDC) will present findings from a first-of-its-kind report examining levels of stigma and discrimination surrounding people living with hepatitis in Europe. The report finds that half (50%) of those living with hepatitis B and C struggle to tell people about their hepatitis. Around a quarter of people living with hepatitis B and C report they have not told their family (23%) or friends (25%) about their hepatitis.

Eliminating the stigma surrounding hepatitis through the introduction of policies and structural changes has been named as a key factor in hepatitis elimination by the World Health Organization (WHO).

On the opening day of the Summit, WHO will release its 2024 Global Hepatitis Report. It is the first consolidated report on viral hepatitis epidemiology, service coverage and product access, with improved data for action. With information from 187 countries, the report outlines regional perspectives and actionable steps to scale up interventions, emphasising the importance of leveraging lessons from the COVID-19 response. A standalone press release will be issued by WHO on 9 April.

About the World Hepatitis Summit

The World Hepatitis Summit is organised by the World Hepatitis Alliance, with the support of the Ministry of Health of Portugal and co-sponsored by WHO. Its mission is to support countries in meeting the targets needed to eliminate viral hepatitis. It is being held in Lisbon and virtually. More information: http://worldhepatitissummit.org/ and https://www.worldhepatitisalliance.org/.

About Viral Hepatitis

Viral hepatitis is inflammation of the liver caused by a virus. WHO says that the total deaths cause by viral hepatitis, including acute cases, cirrhosis and liver cancer, accounted for 1.1 million deaths globally in 2019. In total, over 350 million people in the world are living with viral hepatitis. Each year, over a million people lose their lives because of conditions related to acute hepatitis and chronic infection that cause liver cancer and cirrhosis.

Contact Information

James Gillies
Communications Contact
james.gillies@worldhepatitisalliance.org
00447932328287

Steve Shaw
Marketing Manager
steve.shaw@worldhepatitisalliance.org

SOURCE: World Hepatitis Alliance (WHA)

.

View the original press release on newswire.com.

More from this category

  • Medical Health Aged Care
  • 31/10/2024
  • 17:55
Kyowa Kirin Co., Ltd.

Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company’s 2030…

  • Contains:
  • Medical Health Aged Care
  • 31/10/2024
  • 12:10
MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study,…

  • Business Company News, Medical Health Aged Care
  • 31/10/2024
  • 11:03
Firebrick Pharma

Agreement Signed to Market Nasodine to Healthcare Professionals in Singapore

Firebrick Pharmais pleased to announce that it has executed a Marketing Representation Agreement (the “Agreement”) with Singapore-based, Innorini, trading as Innorini Life Sciences (“Innorini”). The initial term of the Agreement is one year with the option to renew for subsequent one-year terms by mutual agreement. Under the Agreement, Innorini will undertake “Marketing Services” commencing 1 November 2024. The Marketing Services comprise sampling and promotion of Nasodine® Nasal Spray (“Nasodine”) to General Practitioners (“GPs”) and hospital-based doctors and pharmacists (collectively “HCPs”) in Singapore. In addition to building awareness and support of Nasodine by HCPs, Innorini will be expected to sell Nasodine…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.